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E-mail address: wanghq_doctor@hotmail.com (H.-TNF-related apoptosis-inducing ligand (TRAIL) is currently considered a promising target for devel-
oping anti-cancer therapies. Accumulating evidences have now shown that oxidative stress is
involved in the TRAIL-mediated cell death. The peroxiredoxins (PRDXs) are a ubiquitous family of
proteins involved in protection against oxidative stress through the detoxiﬁcation of cellular perox-
ides. Here we demonstrated that endogenous expression of PRDX4 was signiﬁcantly decreased by
TRAIL at the transcriptional level. In addition, overexpression of PRDX4 dramatically suppressed
TRAIL-induced apoptosis. Taken together, these data for the ﬁrst time suggested that TRAIL sup-
pressed the PRDX4 gene at the transcriptional level and that downregulation of PRDX4 might facil-
itate cell death induced by TRAIL.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
TNF-related apoptosis-inducing ligand (TRAIL) is now consid-
ered to be a promising anticancer reagent, since its selective cyto-
toxicity in transformed tumor cells but not in normal cells [1,2].
TRAIL engages the extrinsic apoptotic pathway by binding to its
membrane-bound death receptors (DR4 and DR5), an event fol-
lowed by recruitment of intracellular adaptor molecule FADD
and apoptosis initiator procaspase-8, forming the death-inducing
signaling complex (DISC). When caspase-8 is cleaved, active frag-
ment of caspase-8 is released into the cytosol where executioner
of apoptosis, caspase-3 is activated for apoptosis [3]. The activation
of caspase-8 by TRAIL induces the translocation of other cytosolic
proapoptotic proteins to the mitochondria, causing a dissipation
of the mitochondrial membrane potential [4]. Consequently, mito-
chondria release reactive oxygen species (ROS) and pro-apoptotic
proteins into the cytoplasm thus inducing cellular and DNA dam-
age [5]. The activation of pro-caspase-8 is believed to be dependent
solely on proximity to other pro-caspase-8 units during recruit-
ment to the DISC [6]. However, accumulating evidences suggested
that whereas proximity is required for activation of pro-caspase-8,
ROS could modulate the initiation of apoptosis signaling [7–10].
Peroxiredoxins (PRDXs) comprise an extended family of small
antioxidant proteinswhich conserve a thioredoxin-dependent cata-
lytic function that can contribute to cell protection fromROS [11,12].
PRDXs perform their protective antioxidant role in cells through
their peroxidase activity whereby hydrogen peroxide, peroxynitritechemical Societies. Published by E
Q. Wang).and a wide range of organic hydroperoxides are reduced and detox-
iﬁed [12]. At least six PRDXs were identiﬁed in mammalian cells
[11,12]. In human, PRDX1–4, the typical 2-Cys subgroup, share
two conserved motifs centered on Cys residues, which contain an
additional ‘resolving’ cysteine near the C-terminus. PRDX5 differs
because its C-terminal cysteine is not in the conserved position
[13,14]. PRDX6 conserves only the Cys nearer the NH2-terminus,
which is the catalytic site. PRDXareubiquitously andabundantly ex-
pressed in the various tissues of the human body [15] and were re-
ported to act in a mutually non-redundant and sometimes stress-
speciﬁc fashion to protect human cells from oxidant injury [16].
ROS generation is one of the critical events in TRAIL-induced
cancer cell death, but the role of PRDXs during TRAIL treatment
has not been explored. We found that TRAIL speciﬁcally sup-
pressed PRDX4 expression at the transcriptional level. In some can-
cer cells TRAIL did not cause cell death in spite of PRDX4 decrease.
However, our data indicated that subtraction of PRDX4 during
apoptosis, although not sufﬁcient for initiation of apoptosis, is
probably relevant in promoting cell death, since overexpression
of PRDX4 dramatically suppressed TRAIL-induced apoptosis. Our
data suggested that although PRDX4 suppression per se was not
sufﬁcient to induce cell death, its downregulation might facilitate
cell death induced by TRAIL.
2. Materials and methods
2.1. Cell culture
The panel of cancer cells were maintained in DMEM (Sigma–Al-
drich, Saint Louis,MO) supplementedwith10%FBS (Sigma–Aldrich).lsevier B.V. All rights reserved.
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Fig. 1. The effect of TRAIL exposure on the PRDXs expression. (A) 8 h after cells had
been treated with 1000 ng/ml TRAIL, total cellular RNA was extracted and real-time
RT-PCR was performed. (B) HeLa cells were treated with 1000 ng/ml TRAIL for 8 h,
total cellular proteins were isolated and Western blot was performed using
indicated antibodies. A representative image was presented and the ratios vs that of
vehicle-treated (normalized by tubulin) were graphed on the right of the image
(n = 3). C, A panel of cancer cells was treated with 1000 ng/ml TRAIL for 8 h and
PRDX4 expression was measured using real-time RT-PCR. All experiments were
repeated three times, and each experimental condition was repeated in triplicate in
each experiment. Data reported were average values ±S.D. of representative
experiments. *P < 0.01 as compared with vehicle-treated.
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Human recombinant TRAIL and actinomycin D were purchased
from Calbiochem (San Diego, CA) and Sigma–Aldrich (Saint Louis,
MO), respectively. Western immunoblotting was performed using
primary antibodies against PRDX1 (Novus Biologicals Inc., Littleton,
CO), PRDX2 (GeneTex Inc., San Antonio, TX), PRDX3 (Novus Biolog-
icals Inc.), PRDX4 (Abcam, Cambridge, MA), PRDX5 (Abnova, Wal-
nut, CA), PRDX6 (Abcam), cytochrome c (BD Bioscience, San Jose,
CA), poly ADP-ribose polymerase (PARP) (Cell Signaling Technol-
ogy, Danvers, MA) or c-tubulin (Sigma, Saint Louis, MO).
2.3. RNA isolation and real-time reverse transcription-polymerase
chain reaction (RT-PCR)
RNA isolation and real-time RT-PCR were performed as previ-
ously reported [17]. 50-CACAGCTGTTATGCCAGATG-30 and 50-ACT
GAAAGCAATGATCTCCG-30, 50-AGATCATCGCGTTCAGCAAC-30 and
50-ATCCTCAGACAAGCGTCTGG-30, 50-GTCGCAGTCTCAGTGGATTC-
30 and 50-AACAGCACACCGTAGTCTCG-30, 50-AACAGCTGTGATCGA
TGGAG-30 and 50-TCAAGTCTGTCGCCAAAAGC-30, 50-CAAGAAGGG
TGTGCTGTTTG-30 and 50-TAACACTCAGACAGGCCACC-30, 50-ATGCC
TGTGACAGCTCGTGTG-30 and 50-TCTTCTTCAGGGATGGTTGG-30
primer pairs were used to amplify PRDX1–6, respectively. For
b-actin, the forward primer was 50-GAGACCTTCAACACCCCAGCC-30
and the reverse was 50-GGATCTTCATGAGGTAGTCAG-30. Results
were normalized against those of b-actin.
2.4. Isolation of cytosolic and mitochondrial fractions
Cytosolic and mitochondrial fractions from HeLa cells were pre-
pared as previously described [18].
2.5. Western blot analysis
Cells were lysed in lysis buffer (20 mM Tris–HCl, 150 mM NaCl,
2 mM EDTA, 1% Triton-X100 and protease inhibitor cocktail
(Sigma–Aldrich). Cell extract protein amounts were quantiﬁed
using the BCA protein assay kit. Equivalent amounts of protein
(25 lg) were separated using 12% SDS–PAGE and transferred to
PVDF membrane (Millipore Corporation, Billerica, MA).
2.6. Generation of PRDX4 promoter luciferase constructs
The 50-ﬂanking region of human PRDX4 genomic DNA between
979 and +24 (+1 represents the translation start site, and the up-
stream nucleotide adjacent to the transcription start site is deﬁned
here as 1) was ampliﬁed by PCR from HeLa genomic DNA and
subcloned into the reporter plasmid pGL4 (Promega, Madison, WI).
2.7. Luciferase assay
The luciferase activity was determined using the Dual-Lucifer-
ase Reporter Assay System (Promega), according to the manufac-
turer’s instructions. All transfection experiments were repeated for
three times in triplicate. Fireﬂy (Photinus pyralis) luciferase activi-
ties normalized by Renilla (Renilla reniformis) activities are pre-
sented as fold induction relative to the normalized ﬁreﬂy
luciferase activity in cells transfected with the pGL4 empty vector
only, which was taken as 1.0.
2.8. Construction of PRDX4 plasmid and generation of HeLa cells stably
overexpressing PRDX4
A cDNA encoding human PRDX4 was generated by polymerase
chain reaction (PCR) from human brain cDNA library (Invitrogen,Carlsbad, CA) and subcloned into the eukaryotic expression plas-
mid pcDNA3 (pcDNA3-PRDX4). HeLa cells were transfected with
pcDNA3-PRDX4 or an empty vector (pcDNA3-Flag) using Lipofect-
amine 2000 according to the protocol of the manufacturer. 48 h
later, the cells were incubated in growth medium containing
G418 (800 lg/ml, Life Technologies) to select stable clones. Four
stable clones were selected based on the overexpression of PRDX4,
which was conﬁrmed by Western blotting.
2.9. Detection of cell death
For cell death assays, cells were washed twice in phosphate-
buffered saline and then stained with Annexin V-FITC (Biovision,
Mountainview, CA) and propidium iodide (PI, Sigma–Aldrich)
according to the manufacturer’s instructions. After staining with
annexin V-FITC and PI, samples were analyzed by ﬂuorescence-
activated cell scanner (FACScan) ﬂow cytometer (Becton Dickinson,
Franklin Lakes, NJ).
H.-Q. Wang et al. / FEBS Letters 583 (2009) 1511–1515 15132.10. Measurement of intracellular ROS levels
The average level of intracellular ROS in thyroid cancer cells was
evaluated in cells loaded with the redox-sensitive dye DCFH-DA
(Molecular Probes, OR). Cells were washed twice in a phosphate-
buffered saline (PBS) and stained in the dark for 30 min with
20 lMDCFH-DA and harvested. Cells were dissolvedwith 1% Triton
X-100, and ﬂuorescence was measured at an excitation wavelength
of 485 nm and an emission wavelength using a ﬂuorescence spec-
trometer (HTS 7000, Perkin–Elmer, Boston,MA). A duplicate culture
with the same treatments was used to determine the total protein
levels. The ROS levels were expressed as arbitrary unit/mg protein,
then as the percentage of control.
2.11. Statistics
The statistical signiﬁcance of the difference was analyzed by
ANOVA and post hoc Dunnett’s test. Statistical signiﬁcance was de-
ﬁned as P < 0.05. All experiments were repeated three times, and
data were expressed as the mean ± S.D. (standard deviation) from
a representative experiment.
3. Results
3.1. Suppression of PRDX4 mRNA/protein expressions by TRAIL
exposure
We ﬁrst performed real-time RT-PCR to study PRDXs mRNA
expression regulation by TRAIL in HeLa cells. TRAIL had no obvious
effect on the mRNA expression levels of PRDX1, PRDX2, PRDX3,
PRDX5 and PRDX6 (Fig. 1A). However, incubation with TRAIL sig-Vehicle
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Fig. 2. Suppression of PRDX4 expression by TRAIL at the transcriptional level. (A)
HeLa cells were pretreated with 20 lg/ml actinomycin D for 1 h, and incubated with
vehicle or 1000 ng/ml TRAIL for an additional 8 h. Extracted RNAs were then
processed to real-time RT-PCR. (B) 24 h after transfected with pPRDX4 promoter
construct, HeLa cells were treated with indicated concentrations of TRAIL for 8 h
and harvested for measuring luciferase activities. All experiments were repeated
three times, and each experimental condition was repeated in triplicate in each
experiment. Data reported were average values ±S.D. of representative experi-
ments. *P < 0.01 as compared with vehicle-treated.niﬁcantly decreased PRDX4 mRNA levels in HeLa cells (Fig. 1A).
Western blot analysis also demonstrated a signiﬁcant decrease in
PRDX4 protein expression by TRAIL treatment (Fig. 1B). These re-
sults indicated that endogenous PRDX4 mRNA/protein expressions
in HeLa cells were both suppressed by TRAIL exposure. To assess
whether downregulation of PRDX4 by TRAIL was a cell-speciﬁc re-
sponse, we investigated RPDX4 expression in a panel of cancer cells
derived from various histological tissues and found that TRAIL
inhibited PRDX4 expression in all cancer cells tested (Fig. 1C).
3.2. Effect of TRAIL on PRDX4 mRNA stability
To examine whether the effect of TRAIL on PRDX4 mRNA de-
crease was due to decrease of PRDX4 mRNA stability or transcrip-
tional suppression, we pretreated HeLa with vehicle or TRAIL for
8 h, then treated with 10 lg/ml actinomycin D for an additional
indicated hours. PRDX4 mRNA in HeLa treated with vehicle
(control) degraded approximately by 50% after 8 h treatment with
actinomycin D (Fig. 2A). When HeLa cells were pretreated with
TRAIL, PRDX4 mRNA degradation was not affected (Fig. 2A). These
results suggested that TRAIL did not affect PRDX4 mRNA stability.
We next investigated whether TRAIL exposure can suppress the
promoter activity of the PRDX4 gene in HeLa cells. pGL4-luc, in
which the 50-ﬂanking region of human PRDX4 genomic DNA be-
tween 979 and +24 (+1 represents the transcription start site)
was inserted upstream of a luciferase reporter, was transiently
transfected into HeLa cells, and the luciferase activity was mea-
sured 8 h after exposure to TRAIL. TRAIL signiﬁcantly decreased
pPRDX4/979 activity in a dose-dependent manner (Fig. 2B).
These results suggested that TRAIL suppressed PRDX4 expression
at the transcriptional level.
3.3. Downregulation of PRDX4 per se is not sufﬁcient to initiate cell
death
TRAIL-induced loss of PRDX4 occurred ahead of cleavage of
PARP, the well known substrate of caspase-3 (Fig. 3A), as well as
mitochondrial release of cytochrome c (Fig. 3B). In addition, TRAIL
decreased PRDX4 expression in all cancer cells tested, while some
types of cancer cells were resistant to TRAIL-induced cell demise
(Fig. 3C). Collectively, these data suggested that TRAIL-mediated
downregulation of PRDX4 per se might not be sufﬁcient to initiate
apoptosis.
3.4. Overexpression of PRDX4 inhibits TRAIL-induced apoptosis
Next, we examined the functional signiﬁcance of TRAIL-induced
downregulation of PRDX4 in apoptosis. To test whether PRDX4
overexpression could block the cell death by TRAIL, we employed
HeLa cells stably transfected with PRDX4 (HeLa/PRDX4) and empty
vector (HeLa/vector). Four different clones overexpressing several
folds of PRDX4 were selected (Fig. 4A). The previously described
TRAIL-mediated downregulation of PRDX4 expression was also ob-
served in PRDX4 stable cells but with a lesser extent (Fig. 4B). Ec-
topic expression of PRDX4 signiﬁcantly suppressed TRAIL-induced
apoptosis (Fig. 4C), while had little effects on ROS generation
(Fig. 4D), suggesting that downregulation of PRDX4 mediated by
TRAIL might promote cell death independent of ROS production.4. Discussion
TRAIL, a recently identiﬁed member of the tumor necrosis factor
family, is capable of inducing apoptosis in various tumor cells
[19,20]. Since it induces apoptosis in a variety of neoplastic cells
while displaying minimal or absent cytotoxicity to most normal
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ment of anticancer therapies. Accumulating lines of evidence have
now demonstrated that ROS is necessary to initiate TRAIL-mediated
apoptosis in some carcinoma cells [7–10,21].
In eukaryotic cells, PRDXs not only act as antioxidants against
ROS, but also inﬂuence processes such as apoptosis, cell-differenti-
ation and proliferation [22]. PRDXs are ubiquitously and abun-
dantly expressed in the various tissues of the human body [15].
These enzymes are produced at high levels in cells: they are the sec-
ond or third most abundant protein in erythrocytes and compose
0.1–0.8% of the soluble protein in other mammalian cells [23].
Many organisms producemore than one isoform of PRDX, including
at least six PRDXs identiﬁed in mammalian cells, which are distrib-
uted differentially within cells: PRDX1, 2, and 4 are localized to the
cytosol; PRDX3 is restricted to mitochondria; PRDX4 is located in
ER and also extracellularly secreted; and PRDX5 is located in mito-
chondria and peroxisomes [11,12]. PRDXs contain a reactive Cys in
a conserved region near the N-terminus, and this catalytic Cys res-
idue forms cystein–sulfenic acid as a reaction intermediated during
the reduction of peroxide. All the PRDXs exhibit peroxidase activity
dependent on reduced forms of thioredoxin and/or glutathione.
PRDX1–4 has an additional Cys at a conserved position near the
C-terminus. PRDXs are not redundant functionally and individual
PRDXs may protect against different stresses [16]. In this context,
it is interesting to note that only PRDX4 expressionwas altered dur-
ing TRAIL exposure. Mammals possess six PRDX isoforms with cel-
lular locations including the cyotosol (PRDX1, 2, 6), nucleus
(PRDX1), motochondria (PRDX3, 6) and peroxisomes (PRDX5).
PRDX4 has been described as both an endoplasmic reticulum pro-
tein and as a secreted protein [24–26]. TRAIL signiﬁcantly de-
creased PRDX4 mRNA expression level in multiple cancer cells
derived from different histology. In addition, TRAIL also decreased
PRDX4 protein expression level. TRAIL did not affect PRDX4 mRNA
stability and PRDX4 gene promoter activity was inhibited by TRAIL,
suggesting that PRDX4 expression was suppressed at the transcrip-
tional level. While PRDX4 downregulation per se may not be sufﬁ-cient to induce cell death, PRDX4 suppression has some favorable
clinical efﬁcacy in the cancer therapy, since overexpression signiﬁ-
cantly suppressed TRAIL-mediated cell death. In addition, PRDX4
overexpression had little effects on ROS generation, suggesting that
the effects witnessed following PRDX4 overexpression may be
attributable to its presence helping to alleviate the after-effects of
oxidative insult, consisting with previous report [26].
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